Articles published by Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference

October 15, 2026

Tickers RCKT

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

October 07, 2026

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital

October 06, 2026

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease

September 15, 2026

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

September 03, 2026

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress

August 10, 2026

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

August 03, 2026

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

June 12, 2026

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

May 28, 2026

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

May 07, 2026

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

April 28, 2026

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

March 27, 2026

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

February 26, 2026

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

February 23, 2026

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

November 25, 2025

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

November 06, 2025

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

October 14, 2025

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 10, 2025

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

August 28, 2025

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

August 07, 2025

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs

July 24, 2025

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy

July 17, 2025

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy

June 30, 2025

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease

May 27, 2025

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy

May 15, 2025

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy

May 09, 2025

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress

May 08, 2025

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

April 03, 2025

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

February 27, 2025

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Tickers RCKT

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.